StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGN – Free Report) in a research note released on Saturday morning. The brokerage issued a sell rating on the medical research company’s stock.
OpGen Price Performance
NASDAQ:OPGN opened at $1.60 on Friday. The business’s 50-day simple moving average is $1.86 and its two-hundred day simple moving average is $2.61. OpGen has a 52 week low of $1.46 and a 52 week high of $9.90.
OpGen (NASDAQ:OPGN – Get Free Report) last announced its quarterly earnings results on Monday, August 19th. The medical research company reported ($1.18) EPS for the quarter. The company had revenue of $0.03 million during the quarter.
About OpGen
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
Featured Articles
- Five stocks we like better than OpGen
- Roth IRA Calculator: Calculate Your Potential Returns
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- There Are Different Types of Stock To Invest In
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- When to Sell a Stock for Profit or Loss
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.
